Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in GAD

summarizeSummary

Protagenic Therapeutics received FDA pre-IND feedback supporting its planned IND for PT00114 in generalized anxiety disorder, with no objections to the Phase 1 program design or CMC packages. IND submission is planned for Q4 2026.

check_boxKey Events · Product Development and Regulatory · PTIX

• FDA Pre-IND Feedback Received

  FDA provided written responses to the Type B pre-IND meeting request for PT00114 in GAD, raising no objection to the planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages.

• IND Submission Timeline

  Company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027, subject to FDA review and clearance.

• Regulatory Path Cleared

  FDA identified no clinical hold issues and did not identify deficiencies that would preclude submission of an IND, allowing the company to carry forward prior ex-U.S. clinical experience.

• Going Concern Context

  The company has a going concern warning and cash runway only until about the end of Q3 2026, making this regulatory progress critical for its ability to raise additional capital.

auto_awesomeAnalysis · PTIX · Life Sciences

The FDA raised no objection to the planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages for PT00114 in generalized anxiety disorder. This clears a key regulatory hurdle and keeps the IND submission on track for Q4 2026, with first patient dosing targeted for H1 2027. The company faces a going concern warning and limited cash runway, so this positive regulatory feedback is critical for its survival and ability to raise capital.